Chinese Journal of Dermatology ›› 2018, Vol. 51 ›› Issue (1): 72-75.doi: 10.3760/cma.j.issn.0412-4030.2018.01.025
Previous Articles Next Articles
Xiao-Li SUN1,
Received:2017-05-22
Revised:2017-07-09
Online:2018-01-15
Published:2018-01-11
Xiao-Li SUN. Diagnosis and treatment of moderate-to-severe atopic dermatitis[J].Chinese Journal of Dermatology, 2018, 51(1): 72-75.
| ［1］ | Kraft M, Worm M. Dupilumab in the treatment of moderate⁃to⁃severe atopic dermatitis［J］. Expert Rev Clin Immunol, 2017, 13（4）: 301⁃310. DOI: 10.1080/1744666X.2017.1292134.<br /> |
| ［2］ | Hamilton JD, Suárez⁃Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2014, 134（6）: 1293⁃1300. DOI: 10.1016/j.jaci.2014.10.013.<br /> |
| ［3］ | Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2016, 138（2）: 336⁃349. DOI: 10.1016/j.jaci.2016.06.010.<br /> |
| ［4］ | Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation［J］. Immunol Rev, 2011, 242（1）: 233⁃246. DOI: 10.1111/j.1600⁃065X.2011.01027.x.<br /> |
| ［5］ | Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis［J］. Curr Allergy Asthma Rep, 2015, 15（11）: 65. DOI: 10.1007/s11882⁃015⁃0567⁃4.<br /> |
| ［6］ | Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. management and treatment of atopic dermatitis with topical therapies［J］. J Am Acad Dermatol, 2014, 71（1）: 116⁃132. DOI: 10.1016/j.jaad.2014. 03.023.<br /> |
| ［7］ | Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. management and treatment with phototherapy and systemic agents［J］. J Am Acad Dermatol, 2014, 71（2）: 327⁃349. DOI: 10.1016/j.jaad.2014.03. 030.<br /> |
| ［8］ | 张建中. 特应性皮炎的诊断标准发展及评价［J］. 中华皮肤科杂志, 2017, 50（1）: 67⁃69. DOI: 10.3760/cma.j.issn.0412⁃4030. 2017.01.025.<br /> |
| ［9］ | Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients［J］. J Eur Acad Dermatol Venereol, 2016, 30（5）: 729⁃747. DOI: 10.1111/jdv.13599.<br /> |
| ［10］ | Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2010, 24（3）: 317⁃328. DOI: 10.1111/j.1468⁃3083.2009.03415.x.<br /> |
| ［11］ | Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） part I［J］. J Eur Acad Dermatol Venereol, 2012, 26（8）: 1045⁃1060. DOI: 10.1111/j.1468⁃3083. 2012.04635.x.<br /> |
| ［12］ | Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） Part II［J］. J Eur Acad Dermatol Venereol, 2012, 26（9）: 1176⁃1193. DOI: 10.1111/j. 1468⁃3083.2012.04636.x.<br /> |
| ［13］ | Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014, 70（2）: 338⁃351. DOI: 10.1016/j.jaad.2013.10.010.<br /> |
| ［14］ | Saeki H, Nakahara T, Tanaka A, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016［J］. J Dermatol, 2016, 43（10）: 1117⁃1145. DOI: 10.1111/1346⁃8138. 13392.<br /> |
| ［15］ | 中华医学会皮肤性病学分会免疫学组、特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2014版）［J］. 中华皮肤科杂志, 2014, 47（7）: 511⁃514. DOI: 10.3760/cma.j.issn.0412⁃4030. 2014.07.018.<br /> |
| ［16］ | Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. Exp Dermatol, 2017, 26（1）: 28⁃35. DOI: 10.1111/exd.13112.<br /> |
| ［17］ | Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite （bleach） baths in patients with moderate to severe atopic dermatitis in Malaysia［J］. J Dermatol, 2013, 40（11）: 874⁃880. DOI: 10.1111/1346⁃8138.12265.<br /> |
| ［18］ | Kim HS, Lee JH, Roh KH, et al. Clinical Trical of human umbilical cord blood⁃derived stem cells for the treatment of moderate⁃to⁃severe atopic dermatatitis: phase I/IIa studies［J］. Stem Cells, 2017, 35（1）: 248⁃255. DOI: 10.1002/stem.2401.<br /> |
| ［19］ | Edwards AM, Bibawy D, Matthews S, et al. Long⁃term use of a 4 sodium cromoglicate cutaneous emulsion in the treatment of moderate to severe atopic dermatitis in children［J］. J Dermatolog Treat, 2015, 26（6）: 541⁃547. DOI: 10.3109/09546634.2015. 1034077.<br /> |
| ［20］ | Mehrbania M, Choopani R, Fekri A, et al. The efficacy of whey associated with dodder seed extract on moderate⁃to⁃severe atopic dermatitis in adults: a randomized, double⁃blind, placebo⁃controlled clinical trial［J］. J Ethnopharmacol, 2015, 172: 325⁃332. DOI: 10.1016/j.jep.2015.07.003.<br /> |
| ［21］ | Nicol NH, Boguniewicz M, Strand M, et al. Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program［J］. J Allergy Clin Immunol Pract, 2014, 2（4）: 400⁃406. DOI: 10.1016/j.jaip.2014.04.009.<br /> |
| ［22］ | Gu SX, Zhang AL, Coyle ME, et al. Chinese herbal medicine granules （PTQX） for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial［J］. Trials, 2015, 16: 294. DOI: 10.1186/s13063⁃015⁃0806⁃y.<br /> |
| ［23］ | 孙彩虹, 顾恒. 不同国家和地区特应性皮炎治疗指南解读［J］. 中华皮肤科杂志, 2017, 50（03）: 215⁃218. DOI: 10.3760/cma.j.issn.0412⁃4030.2017.03.017.<br /> |
| ［24］ | Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis［J］. Clin Dermatol, 2016, 34（5）: 607⁃613. DOI: 10.1016/j.clindermatol.2016.05.011.<br /> |
| ［25］ | Nicole NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis［J］. Immunol Allergy Clin North Am, 2017, 37（1）: 123⁃139. DOI: 10.1016/j.iac.2016.08.003.<br /> |
| ［26］ | Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate⁃to⁃severe atopic dermatitis: a systematic review［J］. J Allergy and Clin Immunol, 2014; 133（2）: 429⁃438. DOI: 10.1016/j.jaci.2013.07.049.<br /> |
| ［27］ | FDA approves new eczema drug Dupixent. March 28, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549078.htm.<br /> |
| ［28］ | Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled, phase II study［J］. Br J Dermatol, 2017, DOI: 10.1111/bjd.15493.<br /> |
| ［29］ | Heratizadeh A, Werfel T. Anti⁃inflammatory therapies in atopic dermatitis［J］. Allergy, 2016, 71（12）: 1666⁃1675.DOI: 10.1111/all.13065.<br /> |
| ［30］ | Saleem MD, Oussedik E, D′Amber V, et al. Interleukin⁃31 pathway and its role in atopic dermatitis: a systematic review［J］. J Dermatolog Treat, 2017, 2: 1⁃9. DOI: 10.1080/09546634.2017. 1290205.<br /> |
| ［31］ | Ruzicka T, Hanifin JM, Furue M, et al. Anti⁃Interleukin⁃31 Receptor a antibody for atopic dermatitis［J］. N Engl J Med, 2017, 376: 826⁃835. DOI: 10.1056/NEJMoa1606490.<br /> |
| ［32］ | Montes⁃Torres A, Llamas⁃Velasco M, Pérez⁃Plaza A, et al. Biological treatments in atopic dermatitis［J］. J Clin Med, 2015, 4（4）: 593⁃613. DOI: 10.3390/jcm4040593.<br /> |
| ［33］ | Guttman⁃Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopicdermatitis［J］. Expert Opin Biol Ther, 2013, 13（4）: 549⁃561. DOI: 10.1517/14712598.2013.758708.<br /> |
| ［34］ | Saporito RC, Cohen DJ. apremilast use for moderate⁃to⁃severe atopic dermatitis in pediatric patients［J］. Case Rep Dermatol , 2016, 8（2）: 179⁃184. DOI: 10.1159/000446836.<br /> |
| ［35］ | FDA approves Eucrisa for eczema. December 14, 2016. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm.<br /> |
| No related articles found! |
|
